Sono-Tek Corp (SOTK) Q1 2027 Financial Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended May 31, 2026 (First Quarter of Fiscal Year 2027). Sono-Tek Corporation is a global leader in designing and manufacturing ultrasonic coating systems for microelectronics, medical devices, alternative energy, and industrial markets. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2027 (May 31, 2026) | Q1 2026 (May 31, 2025) |
|---|---|---|
| Net Sales | $5,661,159 | $5,132,773 |
| Gross Profit | $3,213,918 | $2,664,514 |
| Gross Margin | 57% | 52% |
| Operating Income | $897,160 | $483,368 |
| Net Income | $741,168 | $484,985 |
| Diluted EPS | $0.05 | $0.03 |
| Cash & Cash Equivalents | $8,982,075 | $4,863,039 |
| Marketable Securities | $7,669,872 | $7,469,649 |
| Total Debt | $0 | $0 |
| Working Capital | $17,460,978 | $16,235,223 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% year-over-year, driven primarily by a 388% surge in Medical market sales ($3.95M vs $0.81M) and a 345% increase in Industrial sales.
- Margin Expansion: Gross margin expanded 500 basis points to 57%, attributed to a favorable product mix (high-value medical systems) and a concentration of U.S. shipments which reduced distributor discounts.
- Market Shifts: Sales to the Alternative Energy/Clean market declined 90% ($2.93M decrease) due to reduced electrolysis demand and no solar shipments, offsetting growth in other sectors.
- Operating Expenses: Total operating expenses rose 6% to $2.32M. Marketing and selling expenses increased 19% due to higher commissions and trade show costs, while R&D expenses decreased 8%.
- Liquidity: Cash and cash equivalents increased by $1.64M, and total liquid assets (cash + marketable securities) reached $16.65M. The company remains debt-free.
Guidance, Outlook, and Risks
- Backlog: Combined equipment and service backlog increased 3% to $7.73 million as of May 31, 2026.
- Outlook: Management anticipates wide variations in order flow and shipments quarter-to-quarter. Future growth is expected from the transition to higher-value complete machine solutions and expansion in medical and alternative energy markets.
- Customer Concentration: Two customers accounted for 53% of sales in Q1 2027. Two customers also represented 43% of outstanding accounts receivable.
- Risks: Key risks include general economic conditions, supply chain pressures, the recovery of specific end markets (Electronics/Medical), and the impact of tariffs. The company notes that forward-looking statements are subject to inherent uncertainties.
- Unusual Items: No material legal proceedings or contingencies were reported. The company recorded a $57,000 inventory write-off for slow-moving inventory.
Investor Verification Checklist
- Verify the sustainability of the 388% growth in the Medical sector and whether it is driven by one-time large orders.
- Assess the impact of the 90% decline in Alternative Energy sales on future revenue projections.
- Review the concentration risk associated with the top two customers representing over half of quarterly sales.
- Confirm the timeline for the backlog of $7.73 million to convert into recognized revenue.
- Monitor the company's ability to maintain gross margins above 55% as product mix fluctuates.